HealthQuill Eli Lilly
Pfizer Inc., has discontinued its clinical trials of the twice-daily oral weight-loss drug, danuglipron, after more than 50% of the patients opted out due to adverse effects of the medicine.
Drugs Health Pharma

Pfizer Inc., stops twice-daily oral obesity drug trial at mid-stage

HQ Team December 2, 2023: Pfizer Inc., has discontinued its clinical trials of the twice-daily oral weight-loss drug, danuglipron, after more than 50%.

Read More
Eli Lilly’s weight-loss injection Zepbound, taken along as a supplement with diet and exercise, got the USFDA and UK regulator’s nod after clinical trials proved adults lost 48 pounds on average during treatment.
Drugs Medical Pharma

Eli Lilly’s Zepbound outperforms Novo’s Wegovy in weight loss study

HQ team November 28, 2023: A recent comparative analysis of Eli Lilly and Novo Nordisk’s weight loss drugs on diabetes patients showed Eli.

Read More
Eli Lilly, a US company that forecasts revenue of up to $33.9 billion, plans to build a $2.5 billion plant in Germany to make devices for treating diabetes and obesity.
Drugs Health Pharma

Lilly to build $2.5b plant in Germany to make diabetes, obesity devices

HQ Team November 18, 2023: Eli Lilly, a US company that forecasts revenue of up to $33.9 billion, plans to build a $2.5.

Read More
Eli Lilly’s weight-loss injection Zepbound, taken along as a supplement with diet and exercise, got the USFDA and UK regulator’s nod after clinical trials proved adults lost 48 pounds on average during treatment.
Drugs Health Pharma

US, UK regulators give green light to Eli Lilly’s weight-loss treatment

HQ Team November 9, 2023: Eli Lilly’s weight-loss injection Zepbound, to be taken along as a supplement with diet and exercise, got the.

Read More
Eli Lilly and Company announced its experimental drug for treating severe Crohn's disease met secondary targets in efficacy and safety.
Drugs Health Pharma

Eli Lilly late-stage trial drug for Crohn’s disease meets testing goals

HQ Team October 13, 2023: Eli Lilly and Company announced its experimental drug for treating severe Crohn’s disease met secondary targets in efficacy.

Read More
Eli Lilly’s Alzheimer’s experimental drug, donanedab, slowed down cognitive and functional decline in people with early symptoms of the disease, according to a company statement.
Drugs Health Pharma

Eli Lilly: Alzheimer’s test drug slows cognitive decline in early stages

HQ Team July 18, 2023: Eli Lilly’s Alzheimer’s experimental drug, donanedab, slowed down cognitive and functional decline in people with early symptoms of.

Read More
Eli Lilly and Company will acquire private Versanis for $ 1.93 billion in cash to expand its portfolio of obesity drugs, the Indianapolis-based company said in a statement.
Drugs Health Pharma

Eli Lilly to acquire Versanis for $1.9 billion in an obesity drug push

HQ Team July `4, 2023: Eli Lilly and Company will acquire private Versanis for $ 1.93 billion in cash to expand its portfolio.

Read More
Eli Lilly and Company will acquire Dice Therapeutics for $2.4 billion to expand its immunology business, according to an online statement.
Drugs Health Pharma

Eli Lilly to acquire Dice Therapeutics by third quarter for $2.4 billion 

HQ Team June 20, 2023: Eli Lilly and Company will acquire Dice Therapeutics for $2.4 billion to expand its immunology business, according to an.

Read More
Eli Lily sold its sugar-controlling drug to Amphastar Pharmaceuticals for $1.07 billion.
Drugs Health Pharma

Eli Lilly to sell diabetic nasal drug to Amphastar for $1.07 billion 

Eli Lily sold its sugar-controlling drug to Amphastar Pharmaceuticals for $1.07 billion.

Read More
Sanofi, a French pharmaceutical major, announced it would slash the price of insulin, Lantus, by 78% for all U.S. patients with commercial insurance.
Drugs Medical Pharma

Sanofi lowers Lantus insulin costs by 78% in U.S. market

Sanofi, a French pharmaceutical major, announced it would slash the price of insulin, Lantus, by 78% for all U.S. patients with commercial insurance.

Read More